18/12/2025 15:57
Morgan Stanley lowered the target price for CSPC Pharma (01093) to HKD10.4 from HKD11 and maintained the "overweight" rating.
The research house said it now projects sales and recurring net profit growth of +5% and +7% in 2026, accelerating to +6% and +10% in 2027, respectively, as new product launches gain traction.
獨家優惠【etnet x 環球海產】用戶專享全場95折，特價貨品更可折上折。立即使用優惠代碼【ETN1WWS】，選購五星級酒店級海鮮► 立即瀏覽
上一篇新聞︰19/12/2025 14:33 {I-bank focus}Jefferies lowers Xiaomi (01810) to HKD43.36
下一篇新聞︰16/12/2025 16:08 {I-bank focus}Citi raises China Shenhua (01088) to HKD45.1
19/12/2025 16:06 {I-bank focus}Morgan Stanley raises ICBC (01398) to HKD8
16/12/2025 14:43 {I-bank focus}Morgan lowers ZTE (00763) to HKD31.5
15/12/2025 16:00 {I-bank focus}Citi raises Li Ning (02331) to HKD20.6
15/12/2025 14:35 {I-bank focus}Morgan raises Ali Health (00241) to HKD4.6
